I
27.41
0.18 (0.66%)
| Previous Close | 27.23 |
| Open | 27.22 |
| Volume | 1,128,331 |
| Avg. Volume (3M) | 1,612,791 |
| Market Cap | 5,578,817,024 |
| Price / Book | 5.31 |
| 52 Weeks Range | |
| Earnings Date | 6 Feb 2026 |
| Diluted EPS (TTM) | -2.73 |
| Total Debt/Equity (MRQ) | 0.01% |
| Current Ratio (MRQ) | 11.16 |
| Operating Cash Flow (TTM) | -375.87 M |
| Levered Free Cash Flow (TTM) | -227.82 M |
| Return on Assets (TTM) | -37.97% |
| Return on Equity (TTM) | -62.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Immunovant, Inc. | Bullish | Bearish |
AIStockmoo Score
-0.5
| Analyst Consensus | 1.5 |
| Insider Activity | -3.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.50 |
|
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 58.17% |
| % Held by Institutions | 55.78% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 50.00 (Wolfe Research, 82.42%) | Buy |
| Median | 35.00 (27.69%) | |
| Low | 22.00 (Truist Securities, -19.74%) | Hold |
| Average | 35.80 (30.61%) | |
| Total | 3 Buy, 2 Hold | |
| Avg. Price @ Call | 26.48 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 10 Feb 2026 | 35.00 (27.69%) | Buy | 26.68 |
| Guggenheim | 09 Feb 2026 | 44.00 (60.53%) | Buy | 27.49 |
| Truist Securities | 08 Jan 2026 | 22.00 (-19.74%) | Hold | 26.31 |
| Wolfe Research | 06 Jan 2026 | 50.00 (82.42%) | Buy | 25.90 |
| Goldman Sachs | 15 Dec 2025 | 28.00 (2.15%) | Hold | 26.00 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Feb 2026 | Announcement | Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 |
| 23 Jan 2026 | Announcement | Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |